CYP2C19*2/*2, the poor metabolizer, is related to the higher concentration, implying that CYP2C19 testing is still meaningful for precision medicine of Child–Pugh class C cirrhosis patients. This evidence concerns the gene CYP2C19 and Cirrhosis.